Terms: = Leukemia AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2 AND Treatment
13 results:
1. Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Nicosia L; Spencer GJ; Brooks N; Amaral FMR; Basma NJ; Chadwick JA; Revell B; Wingelhofer B; Maiques-Diaz A; Sinclair O; Camera F; Ciceri F; Wiseman DH; Pegg N; West W; Knurowski T; Frese K; Clegg K; Campbell VL; Cavet J; Copland M; Searle E; Somervaille TCP
Cancer Cell; 2023 Dec; 41(12):2136-2153.e13. PubMed ID: 37995682
[TBL] [Abstract] [Full Text] [Related]
2. Ethnic differences in acute promyelocytic leukaemia between New Zealand Polynesian and European patients.
Varghese C; Liu VY; Immanuel T; Chien N; Green T; Chan G; Theakston E; Kalev-Zylinska M
Hematology; 2021 Dec; 26(1):215-224. PubMed ID: 33594940
[TBL] [Abstract] [Full Text] [Related]
3. Role of cholinergic agents in proliferation and caspase activity of hemin-induced erythroid differentiated K562 cells.
Cabadak H; Aydın B
J Recept Signal Transduct Res; 2020 Feb; 40(1):42-48. PubMed ID: 31910706
[No Abstract] [Full Text] [Related]
4. The human T-cell leukemia virus type-1 tax oncoprotein dissociates NF-κB p65
Malu A; Hutchison T; Yapindi L; Smith K; Nelson K; Bergeson R; Pope J; Romeo M; Harrod C; Ratner L; Van Lint C; Harrod R
Virology; 2019 Sep; 535():83-101. PubMed ID: 31299491
[TBL] [Abstract] [Full Text] [Related]
5. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract] [Full Text] [Related]
6. How to use new biology to guide therapy in multiple myeloma.
Morgan GJ; Kaiser MF
Hematology Am Soc Hematol Educ Program; 2012; 2012():342-9. PubMed ID: 23233602
[TBL] [Abstract] [Full Text] [Related]
7. Bortezomib therapeutic effect is associated with expression and mutation of fgfr3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
[TBL] [Abstract] [Full Text] [Related]
9. Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin.
Chang H; Wechalekar A; Li L; Reece D
Cancer Genet Cytogenet; 2004 Jan; 148(1):44-8. PubMed ID: 14697640
[TBL] [Abstract] [Full Text] [Related]
10. Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia.
Dvorak P; Dvorakova D; Doubek M; Faitova J; Pacholikova J; Hampl A; Mayer J
Leukemia; 2003 Dec; 17(12):2418-25. PubMed ID: 14562121
[TBL] [Abstract] [Full Text] [Related]
11. Acrodermatitis continua of Hallopeau in a patient with myelodysplastic syndrome.
van der Kerkhof PC; Steijlen PM; Raymakers RA
Br J Dermatol; 1996 Apr; 134(4):754-7. PubMed ID: 8733386
[TBL] [Abstract] [Full Text] [Related]
12. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.
Chen BK; Saksela K; Andino R; Baltimore D
J Virol; 1994 Feb; 68(2):654-60. PubMed ID: 7507183
[TBL] [Abstract] [Full Text] [Related]
13. Activation of tracheal smooth muscle responsiveness by fMLP-treated HL-60 cells and neutrophils.
Munoz NM; Hamann KJ; Vita A; Cozzi PJ; Baranowski S; Solway J; Leff AR
Am J Physiol; 1993 Mar; 264(3 Pt 1):L222-8. PubMed ID: 8460711
[TBL] [Abstract] [Full Text] [Related]
